Tahseen Mozaffar, Faan

List of Publications by Year
in descending order

50 papers	1,568 citations	331670 21 h-index	330143 37 g-index
53 all docs	53 docs citations	53 times ranked	2444 citing authors

#	Article	IF	Citations
1	An overview of polymyositis and dermatomyositis. Muscle and Nerve, 2015, 51, 638-656.	2.2	176
2	A Review of Spasticity Treatments: Pharmacological and Interventional Approaches. Critical Reviews in Physical and Rehabilitation Medicine, 2013, 25, 11-22.	0.1	145
3	Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurology, The, 2019, 18, 259-268.	10.2	139
4	Genetic landscape and novel disease mechanisms from a large <scp>LGMD</scp> cohort of 4656 patients. Annals of Clinical and Translational Neurology, 2018, 5, 1574-1587.	3.7	129
5	N-Glycan Processing Deficiency Promotes Spontaneous Inflammatory Demyelination and Neurodegeneration. Journal of Biological Chemistry, 2007, 282, 33725-33734.	3.4	91
6	Defining SOD1 ALS natural history to guide therapeutic clinical trial design. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 99-105.	1.9	68
7	Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. Lancet Neurology, The, 2021, 20, 1012-1026.	10.2	59
8	A progressive translational mouse model of human valosinâ€containing protein disease: The VCP^{R155H/+} mouse. Muscle and Nerve, 2013, 47, 260-270.	2.2	58
9	Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study. Molecular Genetics and Metabolism, 2016, 119, 115-123.	1.1	49
10	A randomized <scp>placeboâ€controlled</scp> phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis. Muscle and Nerve, 2022, 65, 291-302.	2.2	41
11	GMPPB-Associated Dystroglycanopathy: Emerging Common Variants with Phenotype Correlation. Human Mutation, 2015, 36, 1159-1163.	2.5	39
12	QuantiMus: A Machine Learning-Based Approach for High Precision Analysis of Skeletal Muscle Morphology. Frontiers in Physiology, 2019, 10, 1416.	2.8	35
13	Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial. Muscle and Nerve, 2019, 59, 201-207.	2.2	35
14	Multisystem proteinopathy: Where myopathy and motor neuron disease converge. Muscle and Nerve, 2021, 63, 442-454.	2.2	33
15	Pulmonary function tests (maximum inspiratory pressure, maximum expiratory pressure, vital capacity,) Tj ETQq1 1 0.784314 rgBT /O… 2016, 26, 136-145.	0.6	31
16	Expanding the importance of HMERF titinopathy: new mutations and clinical aspects. Journal of Neurology, 2019, 266, 680-690.	3.6	31
17	Critically re-evaluating a common technique. Neurology, 2016, 86, 218-223.	1.1	29
18	A stromal progenitor and ILC2 niche promotes muscle eosinophilia and fibrosis-associated gene expression. Cell Reports, 2021, 35, 108997.	6.4	28

#	Article	IF	Citations
19	SMCHD1 mutation spectrum for facioscapulohumeral muscular dystrophy type 2 (FSHD2) and Bosma arhinia microphthalmia syndrome (BAMS) reveals disease-specific localisation of variants in the ATPase domain. Journal of Medical Genetics, 2019, 56, 693-700.	3.2	27
20	Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis. Science Translational Medicine, 2022, 14, eabi9196.	12.4	27
21	Molecular and cellular defects of skeletal muscle in an animal model of acute quadriplegic myopathy. Muscle and Nerve, 2007, 35, 55-65.	2.2	25
22	Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. Muscle and Nerve, 2016, 53, 165-168.	2.2	24
23	IgG regulation through FcRn blocking: A novel mechanism for the treatment of myasthenia gravis. Journal of the Neurological Sciences, 2021, 430, 118074.	0.6	24
24	Longâ€term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses. Annals of Clinical and Translational Neurology, 2021, 8, 1398-1407.	3.7	22
25	Tongue atrophy and fasciculations in transthyretin familial amyloid neuropathy. Neurology: Genetics, 2015, 1, e18.	1.9	20
26	Plasma creatinine and oxidative stress biomarkers in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 263-272.	1.7	20
27	Clinical utility of antiâ€cytosolic 5â€™â€nucleotidase 1A antibody in idiopathic inflammatory myopathies. Annals of Clinical and Translational Neurology, 2021, 8, 571-578.	3.7	18
28	Immunophenotyping of Inclusion Body Myositis Blood T and NK Cells. Neurology, 2022, 98, .	1.1	18
29	Desert hedgehog is a mediator of demyelination in compression neuropathies. Experimental Neurology, 2015, 271, 84-94.	4.1	17
30	Variable clinical features and genotype-phenotype correlations in 18 patients with late-onset Pompe disease. Annals of Translational Medicine, 2019, 7, 276-276.	1.7	13
31	Patient characteristics and comorbidities associated with cerebrovascular accident following acute myocardial infarction in the United States. International Journal of Cardiology, 2014, 175, 323-327.	1.7	11
32	Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of <scp>REGAIN</scp> and its extension study. Muscle and Nerve, 2021, 64, 662-669.	2.2	11
33	A phase 2, double-blinded, placebo-controlled trial of toll-like receptor 7/8/9 antagonist, IMO-8400, in dermatomyositis. Journal of the American Academy of Dermatology, 2021, 84, 1160-1162.	1.2	10
34	Update on immuneâ€mediated therapies for myasthenia gravis. Muscle and Nerve, 2020, 62, 579-592.	2.2	9
35	Homozygosity for the A431E mutation in PSEN1 presenting with a relatively aggressive phenotype. Neuroscience Letters, 2019, 699, 195-198.	2.1	8
36	Homeâ€based gait analysis as an exploratory endpoint during a multicenter phase 1 trial in limb girdle muscular dystrophy type <scp>R2</scp> and facioscapulohumeral muscular dystrophy. Muscle and Nerve, 2022, 65, 237-242.	2.2	8

#	Article	IF	Citations
37	Sporadic inclusion body myositis misdiagnosed as idiopathic granulomatous myositis. Neuromuscular Disorders, 2016, 26, 741-743.	0.6	7
38	A cross-sectional analysis of clinical evaluation in 35 individuals with mutations of the valosin-containing protein gene. Neuromuscular Disorders, 2018, 28, 778-786.	0.6	7
39	Examination of the human motor endplate after brachial plexus injury with twoâ€photon microscopy. Muscle and Nerve, 2020, 61, 390-395.	2.2	6
40	Minocycline-induced skin and dental pigmentations. Neurology, 2006, 67, 2185-2185.	1.1	4
41	Oculopharyngeal Muscular Dystrophy, an Often Misdiagnosed Neuromuscular Disorder: A Southern California Experience. Journal of Clinical Neuromuscular Disease, 2019, 21, 61-68.	0.7	3
42	Patient reported quality of life in limb girdle muscular dystrophy. Neuromuscular Disorders, 2022, 32, 57-64.	0.6	3
43	Novel Therapeutic Options in Treatment of Idiopathic Inflammatory Myopathies. Current Treatment Options in Neurology, 2018, 20, 37.	1.8	2
44	COVID â€19 infection in patients with lateâ€onset Pompe disease. Muscle and Nerve, 2021, , .	2.2	2
45	A Phase 4 Prospective Study in Patients with Adult Pompe Disease Treated with Alglucosidase Alfa. Journal of Neuromuscular Diseases, 2015, 2, S72-S73.	2.6	2
46	Utility of video-fundoscopy and prospects of portable stereo-photography of the ocular fundus in neurological patients. BMC Neurology, 2022, 22, 61.	1.8	2
47	A Phase 4 Prospective Study in Patients with Adult Pompe Disease Treated with Alglucosidase Alfa. Journal of Neuromuscular Diseases, 2015, 2, S72-S73.	2.6	1
48	Attitudes Toward Noninterventional Observational Studies in US and Australian Patients With Sporadic Inclusion Body Myositis. Journal of Clinical Neuromuscular Disease, 2020, 21, 246-247.	0.7	1
49	Diagnostic value of MRI in inflammatory myositis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e128.	6.0	0
50	Random forest: random results or meaningful insights for patients with facioscapulohumeral muscular dystrophy?. Brain, 2021, , .	7.6	0